Nabriva Therapeutics plc (NBRVF)
NBRVF Stock Price Chart
Explore Nabriva Therapeutics plc interactive price chart. Choose custom timeframes to analyze NBRVF price movements and trends.
NBRVF Company Profile
Discover essential business fundamentals and corporate details for Nabriva Therapeutics plc (NBRVF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Aug 2023
Employees
39.00
Website
https://www.nabriva.comCEO
H. Michael Hogan III
Description
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
NBRVF Financial Timeline
Browse a chronological timeline of Nabriva Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 5 Sept 2024
Earnings released on 3 Jun 2024
Earnings released on 18 Oct 2023
EPS came in at -$3.73 .
Earnings released on 29 Sept 2023
EPS came in at -$3.73 , while revenue for the quarter reached $2.57M .
Earnings released on 28 Aug 2023
EPS came in at -$2.72 , while revenue for the quarter reached $7.59M .
Earnings released on 31 Dec 2022
EPS came in at -$7.32 , while revenue for the quarter reached $10.44M .
Earnings released on 30 Sept 2022
EPS came in at -$4.21 , while revenue for the quarter reached $8.78M .
Stock split effective on 16 Sept 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2022
EPS came in at -$4.38 , while revenue for the quarter reached $8.78M .
Earnings released on 31 Mar 2022
EPS came in at -$5.03 , while revenue for the quarter reached $7.67M .
Earnings released on 31 Dec 2021
EPS came in at -$5.89 , while revenue for the quarter reached $8.91M .
Earnings released on 30 Sept 2021
EPS came in at -$5.27 , while revenue for the quarter reached $8.42M .
Earnings released on 30 Jun 2021
EPS came in at -$7.24 , while revenue for the quarter reached $7.75M .
Earnings released on 31 Mar 2021
EPS came in at -$13.23 , while revenue for the quarter reached $2.13M .
Earnings released on 31 Dec 2020
EPS came in at -$27.66 , while revenue for the quarter reached $2.04M .
Stock split effective on 3 Dec 2020
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2020
EPS came in at -$22.38 , while revenue for the quarter reached $569.00K .
NBRVF Stock Performance
Access detailed NBRVF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.